Savara Inc (NASDAQ:SVRA) shares shot up 8.3% during trading on Thursday . The stock traded as high as $1.33 and last traded at $1.31, 323,100 shares changed hands during mid-day trading. A decline of 20% from the average session volume of 404,907 shares. The stock had previously closed at $1.21.
Several research firms have recently commented on SVRA. LADENBURG THALM/SH SH reiterated a “hold” rating and issued a $1.00 price objective on shares of Savara in a report on Thursday, October 3rd. Zacks Investment Research upgraded Savara from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Savara has a consensus rating of “Hold” and an average target price of $9.09.
The company has a market cap of $51.67 million, a PE ratio of -1.02 and a beta of 0.29. The company has a current ratio of 13.07, a quick ratio of 13.07 and a debt-to-equity ratio of 0.23. The business has a fifty day moving average of $0.98 and a 200-day moving average of $2.74.
Large investors have recently made changes to their positions in the stock. Metropolitan Life Insurance Co NY purchased a new position in Savara during the 1st quarter valued at about $83,000. Sullivan Bruyette Speros & Blaney LLC purchased a new position in Savara during the 2nd quarter valued at about $38,000. DekaBank Deutsche Girozentrale increased its holdings in Savara by 67.5% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 20,600 shares of the company’s stock valued at $50,000 after purchasing an additional 8,300 shares during the period. Parametric Portfolio Associates LLC purchased a new position in Savara during the 2nd quarter valued at about $59,000. Finally, United Capital Financial Advisers LLC purchased a new position in Savara during the 2nd quarter valued at about $61,000. Institutional investors own 36.84% of the company’s stock.
About Savara (NASDAQ:SVRA)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Read More: How to trade on quiet period expirations
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.